Avenue Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting continued operating losses and a declining cash position.
Key Highlights
- Net loss of $691 thousand for the three months ended September 30, 2026, compared to a net loss of $692 thousand for the same period in 2025, according to the filing.
- Cash and cash equivalents fell to $1,520 thousand as of September 30, 2026, down from $2,855 thousand at December 31, 2025.
- Total stockholders' deficit of $75 thousand as of September 30, 2026, a shift from stockholders' equity of $1,832 thousand at December 31, 2025.
- Accumulated deficit reached $107,565 thousand as of September 30, 2026, compared to $105,489 thousand at December 31, 2025.
- No revenue was reported for either the three- or nine-month periods ended September 30, 2026, versus $1,404 thousand in other revenue for the nine months ended September 30, 2025.
- Common shares outstanding totaled 3,294,967 as of November 4, 2026, including 111,209 shares issued to Fortress during the nine-month period.
Avenue Therapeutics Reports Third-Quarter 2026 Financial Results
Avenue Therapeutics, Inc. (OTC:ATXI), a Delaware-incorporated biopharmaceutical company headquartered in Bay Harbor Islands, Florida, reported its unaudited consolidated financial results for the quarter ended September 30, 2026. The company disclosed a net loss attributable to common stockholders of $691 thousand for the three-month period, essentially flat compared to the $683 thousand net loss attributable to common stockholders in the same quarter of 2025. On a per-share basis, the filing reported a net loss of $0.20 per common share for the third quarter of 2026, compared to $0.21 for the third quarter of 2025.
For the nine months ended September 30, 2026, the filing disclosed total operating expenses of $2,125 thousand, consisting of $659 thousand in research and development costs and $1,466 thousand in general and administrative expenses. The company recorded no revenue in the nine-month period, in contrast to $1,404 thousand in other revenue during the comparable 2025 period. Net cash used in operating activities for the nine months ended September 30, 2026 was $1,335 thousand, compared to $979 thousand in the prior-year period, according to the filing.
The balance sheet as of September 30, 2026 showed total assets of $1,530 thousand and total liabilities of $1,605 thousand, resulting in a total stockholders' deficit of $75 thousand. The company's Class A Preferred Stock, with 250,000 shares issued and outstanding, carried a $0.0001 par value, and common stock was authorized at up to 200,000,000 shares. Share-based compensation of $169 thousand was recorded for the nine-month period ended September 30, 2026, and 111,209 shares of common stock were issued to Fortress during that same period, the filing stated.
What Was Disclosed
Avenue Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $691 thousand for the quarter, cash of $1,520 thousand, an accumulated deficit of $107,565 thousand, and no revenue for either the three- or nine-month reporting periods.





Please wait processing your request...